Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Tricase

91 clinical trials in Tricase, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Tricase at a glance
91
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

91 trials in Tricase

Open in trial search

Agitation+1

Recruiting

A study to evaluate the safety and effectiveness of dextromethorphan, deramciclane fumarate, and deramciclane in treating agitation in people with Alzheimer's disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dextromethorphan Hydrobromide

Dementia Alzheimer's type

Recruiting

Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:VHB937
  • Sponsor:Novartis Pharma AG

Oesophageal squamous cell carcinoma

Recruiting

Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Colorectal cancer metastatic

Recruiting

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Transitional cell carcinoma

Recruiting

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Chronic lymphocytic leukaemia+2

Recruiting

Clinical Trial of Human Normal Immunoglobulin to Prevent Infections in Patients with Secondary Antibody Deficiency due to CLL, Multiple Myeloma or Non‑Hodgkin Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Grifols Therapeutics LLC

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Revolution Medicines Inc.

Oesophageal adenocarcinoma

Recruiting

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Fondazione GONO G.I.

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Dementia of the Alzheimer's type with delusions

Recruiting

Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fesoterodine
  • Sponsor:Maplight Therapeutics Inc.

Colorectal cancer metastatic

Recruiting

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Pfizer Inc.

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Tricase

What the registry says about research in the country

01 Neurological Disorders

Groundbreaking research focused on neurodegenerative conditions, including trials evaluating novel treatments for Frontotemporal Dementia, Early Alzheimer's Disease, and Amyotrophic Lateral Sclerosis.

  • Frontotemporal Dementia Treatment Study
  • Early Alzheimer's Disease Therapy
  • ALS Disease Progression Research

Studies emphasize safety evaluation and long-term effectiveness of innovative therapeutic approaches.

02 Gastrointestinal Oncology

Advanced research in colorectal cancer and gastric malignancies, with multiple trials exploring targeted therapies and immunotherapy combinations.

  • Metastatic Colorectal Cancer Treatments
  • HER2+ Gastric Cancer Therapy
  • Advanced Pancreatic Cancer Studies

Focus on personalized treatment approaches based on molecular profiles.

03 Hematologic Malignancies

Innovative trials investigating treatments for blood cancers, including studies on Acute Myeloid Leukemia, Follicular Lymphoma, and Diffuse Large B-cell Lymphoma.

  • Leukemia Treatment Optimization
  • Lymphoma Immunotherapy Studies
  • Combination Therapy Approaches

Research emphasizes novel drug combinations and maintenance strategies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.